ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022
Company plans to discuss findings from sepofarsen Illuminate trial w
… (0.25) For these periods the potential exercise of share options is not included in the diluted earnings per share as … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal. … Premium Equity settled Employee Benefit Reserve Option premium on convertible loan Translation Reserve …
Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10
Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1 2020
QR-1123 Investigational New Drug application active for autosomal dominant re
… $15.75 per share including full exercise of underwriters’ option to purchase 862,500 additional ordinary shares. Gross … oligonucleotide QR-110 for treatment of inherited retinal dystrophy in adults and children with LCA10 ○ Structure-based computational approach for optimizing oligonucleotides for A-to-I editing Presented at …
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St
… financial statements, the potential exercise of share options is not included in the diluted earnings per share … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in … Premium Equity settled Employee Benefit Reserve Option premium on convertible loan Translation Reserve …